Table 1. Clinical characteristics of treatment groups.

Variables	Whole cohort N = 20	IVIG+ N = 11	IVIG- N = 9	P
At the time of transplant
Recipient
Female sex, N (%)	8 (40)	5 (45)	3 (33)	0.50
Age, years, mean (SD), range	47 (± 15) (22–75)	45 (± 17) (28–75)	50 (± 15) (22–63)	0.54
Initial nephropathy, N (%)
Glomerular	8 (40)	6 (55)	2 (28)	0.31
Genetic	1 (5)	1 (9)	0 (0)
Other	11 (55)	4 (45)	6 (66)
Dialysis, N (%)	16 (80)	10 (90)	6 (66)	1.00
Time, months, median (Q1-Q3)	49 (33–57)	51 (40–61)	42 (21–89)	0.67
Donor
Deceased, N (%)	17 (85)	9 (81)	6 (66)	1.00
Female sex, N (%)	11 (55)	6 (55)	5 (55)	1.00
Age, years, mean (SD)	49 (±16)	52 (±16)	44 (±17)	0.34
eGFR (ml/min/1,73m2), mean (SD)	89 (±36)	81 (±40)	103 (±27)	0.21
Proteinuria (g/l), median (Q1-Q3)	0.14 (0.07–0.47)	0.14 (0.11–0.68)	0.06 (0.04–0.25)	0.04
Cold ischemia time, hours, mean (SD)	18 (±7)	18 (±5)	18 (±11)	0.90
HLA mismatch
class I, mean (SD)	3 (±1)	3 (±1)	3 (±1)	1.00
class II, mean (SD)	2 (±1)	2 (±1)	3 (±1)	0.23
Anti-HLA antibodies, N (%)	8 (40)	5 (45)	3 (33)	0.32
Donor specific antibodies, N (%)	0 (0)	0 (0)	0 (0)	.
Immunosuppression
Induction, N (%)	20 (100)	11 (100)	9 (100)	1.00
Anti-thymocyte globulin, N (%)	11 (55)	7 (64)	4 (43)	0.63
Interleukin-2 receptor antibody, N (%)	9 (45)	4 (36)	5 (57)
Post-transplant
Maintenance therapy
Steroids, N (%)	20 (100)	11 (100)	9 (100)	0.65
Calcineurin inhibitors, N (%)	20 (100)	11 (100)	9 (100)
Cyclosporine, N (%)	9 (45)	4 (36)	5 (55)
Tacrolimus, N (%)	11 (55)	7 (64)	4 (44)
Mycophenolate mofetil, N (%)	20 (100)	11 (100)	9(100)
Infectious diseases, N (%)
CMV viremia, N (%)	2 (10)	2 (18)	0 (0)	0.49
Before IVIG, N (%)	.	1 (50)	.
BK virus viremia, N (%)	2 (10)	1 (9)	1 (11)	1.00
Before IVIG, N (%)	.	1 (100)	.
Last follow-up
eGFR, ml/min/1.73m2, mean (SD)	56 (±22)	58 (±25)	53 (±20)	0.60
Allograft loss, N (%)	0 (0)	0 (0)	0 (0)	.
Death, N (%)	0 (0)	0 (0)	0 (0)	.